Send me real-time posts from this site at my email

Watchlist Update: 3-14-2019 - ARRY - Array BioPharma - Analyst Comments

Array BioPharma price target raised to $29 from $18 at JPMorgan

JPMorgan analyst Anupam Rama raised his price target for Array BioPharma to $29 from $18 and reiterates an Overweight rating on the shares. The analyst believes the company's fundamentals "remain very solid." The Braftovi / Mektovi launch in BRAF melanoma has exceeded expectations and the interim Phase 3 Beacon study has a high probability of success, Rama tells investors in a research note. Further, the analyst says recent conversations with physicians have reinforced his positive views on Braftovi / Mektovi in melanoma. He sees a favorable risk/reward into the Phase 3 Beacon study.

Read more at:   (source)  $ARRY

$ARRY, Array BioPharma Inc. / H1

NOTE:  This is a medium size biotech play and a high risk/reward potential. It has done very well in the last few months.

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions.

Follow us and check back occasionally for additional articles or comments.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue